Albemarle (NYSE:ALB) Price Target Raised to $215.00

Albemarle (NYSE:ALB) had its price objective increased by Scotiabank from $200.00 to $215.00 in a report released on Wednesday, MarketBeat.com reports. Scotiabank currently has a sector outperform rating on the specialty chemicals company’s stock. Scotiabank also issued estimates for Albemarle’s Q2 2026 earnings at $4.24 EPS, FY2026 earnings at $15.38 EPS and FY2027 earnings at $16.40 EPS.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Albemarle from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Morgan Stanley raised their price objective on Albemarle from $170.00 to $189.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 28th. Argus raised their price objective on Albemarle from $185.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Mizuho lifted their price target on Albemarle from $185.00 to $205.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Albemarle from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Albemarle has a consensus rating of “Moderate Buy” and an average price target of $200.26.

Albemarle Stock Down 5.6%

Shares of ALB stock opened at $180.46 on Wednesday. The stock’s 50 day simple moving average is $182.00 and its 200 day simple moving average is $158.29. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.21 and a current ratio of 2.07. Albemarle has a twelve month low of $53.70 and a twelve month high of $221.00. The company has a market capitalization of $21.28 billion, a price-to-earnings ratio of -52.92, a PEG ratio of 0.96 and a beta of 1.36.

Albemarle (NYSE:ALB) last issued its quarterly earnings data on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $1.71. Albemarle had a positive return on equity of 5.22% and a negative net margin of 5.00%.The business had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.34 billion. During the same period last year, the business earned ($0.18) EPS. The firm’s revenue was up 32.7% compared to the same quarter last year. As a group, research analysts predict that Albemarle will post 12.45 EPS for the current year.

Albemarle Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Friday, June 12th will be paid a $0.405 dividend. The ex-dividend date of this dividend is Friday, June 12th. This represents a $1.62 dividend on an annualized basis and a yield of 0.9%. Albemarle’s payout ratio is currently -47.51%.

Insider Buying and Selling

In other news, CEO J Kent Masters sold 11,783 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $170.81, for a total transaction of $2,012,654.23. Following the transaction, the chief executive officer owned 134,628 shares of the company’s stock, valued at $22,995,808.68. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.42% of the company’s stock.

Institutional Investors Weigh In On Albemarle

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Earnest Partners LLC increased its holdings in Albemarle by 14.6% in the fourth quarter. Earnest Partners LLC now owns 1,630,394 shares of the specialty chemicals company’s stock valued at $230,603,000 after purchasing an additional 207,770 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in Albemarle in the third quarter valued at about $138,723,000. Dimensional Fund Advisors LP increased its holdings in Albemarle by 3.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,475,832 shares of the specialty chemicals company’s stock valued at $119,710,000 after purchasing an additional 52,698 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Albemarle by 1.8% in the third quarter. Northern Trust Corp now owns 1,263,734 shares of the specialty chemicals company’s stock worth $102,464,000 after acquiring an additional 22,856 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Albemarle by 57.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,241,106 shares of the specialty chemicals company’s stock worth $175,542,000 after acquiring an additional 453,881 shares in the last quarter. Institutional investors own 92.87% of the company’s stock.

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.